Lead sponsor
Mayo Clinic
22 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
22
Trials led
10
Ongoing
387,575
Total enrollment
3
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Phase 1/2
1
Phase 2
7
Phase 3
2
Phase 4
8
Not applicable
3
Trials by status
Not yet recruiting
1
By invitation
2
Recruiting
6
Active, not recruiting
1
Completed
11
Withdrawn
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk-not applicableCompleted386,301
Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists-not applicableRecruiting150
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection FractionBMI ≥30Ph 4By invitation81
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes-Ph 2Recruiting60
Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) PatientsFemalePh 1/2Completed52
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With ObesityBMI ≥30Ph 4Recruiting40
Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in ObesityHealthy volunteersPh 2Completed40
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor FunctionsBMI ≥30Ph 4Active, not recruiting30
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal WomenBMI ≥30Ph 4By invitation30